Answers are grounded in this paper and cite their sources.
Aim. To assess the safety of the anti-obesity medications, including one or more (≥1) any adverse events (AEs), ≥1 serious AEs, and major adverse cardiovascular events (MACEs). Materials and methods. A meta-analysis was performed based on the results of blinded Randomized Controlled Trials (RCTs) only. Comparisons in the meta-analysis were made versus placebo. The meta-analysis included studies in which overweight or obesity was a mandatory inclusion criterion for all participants. The presence of type 2 diabetes mellitus and other associated diseases was allowed. Results. The use of almost all of the studied medications for the treatment of obesity or excessive body weight leads to a slight increase in the relative risk (RR) of developing any AEs in a patient within 14%. The risks of developing any serious AEs with the use of tirzepatide, semaglutide, orlistat, and sibutramine were not statistically different from those with placebo. The use of liraglutide increased the RR of developing any serious AEs by 31% versus placebo. The systematic review and meta-analysis showed a reduction in the RR of MACE by 19% with parenteral form of semaglutide (RCT SELECT), as well as no significant differences in the risks of MACE for tirzepatide and liraglutide versus placebo. The effect of orlistat and semaglutide (oral form) on the risk of developing MACE was not assessed due to a lack of data. In RCT SCOUT the use of sibutramine in patients with a history of cardiovascular diseases increased the RR of developing MACE by 14%. Conclusion. Parenteral semaglutide and tirzepatide have a more favorable safety profile in terms of the risk of developing serious AEs, including MACEs.
No takes yet. Share an insight, caveat, or question.
Shchurov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: